271 related articles for article (PubMed ID: 27984656)
1. The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era.
Zumsteg ZS; Lok BH; Ho AS; Drill E; Zhang Z; Riaz N; Shiao SL; Ma J; McBride SM; Tsai CJ; Baxi SS; Sherman EJ; Lee NY
Cancer; 2017 Apr; 123(8):1345-1353. PubMed ID: 27984656
[TBL] [Abstract][Full Text] [Related]
2. The role of concomitant chemoradiotherapy in AJCC 7
Lu DJ; Luu M; Nguyen AT; Shiao SL; Scher K; Mita A; Anderson E; Clair JM; Ho AS; Zumsteg ZS
Oral Oncol; 2020 Nov; 110():104882. PubMed ID: 32650257
[TBL] [Abstract][Full Text] [Related]
3. Survival outcomes in patients with oropharyngeal cancer treated with carboplatin/paclitaxel and concurrent radiotherapy.
Roskies M; Kay-Rivest E; Mascarella MA; Sultanem K; Mlynarek A; Hier M
J Otolaryngol Head Neck Surg; 2016 Oct; 45(1):50. PubMed ID: 27724969
[TBL] [Abstract][Full Text] [Related]
4. Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer.
Frakes JM; Naghavi AO; Demetriou SK; Strom TJ; Russell JS; Kish JA; McCaffrey JC; Otto KJ; Padhya TA; Harrison LB; Trotti AM; Caudell JJ
Cancer; 2016 Feb; 122(4):634-41. PubMed ID: 26565997
[TBL] [Abstract][Full Text] [Related]
5. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.
Marur S; Li S; Cmelak AJ; Gillison ML; Zhao WJ; Ferris RL; Westra WH; Gilbert J; Bauman JE; Wagner LI; Trevarthen DR; Balkrishna J; Murphy BA; Agrawal N; Colevas AD; Chung CH; Burtness B
J Clin Oncol; 2017 Feb; 35(5):490-497. PubMed ID: 28029303
[TBL] [Abstract][Full Text] [Related]
6. Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus.
Münch S; Pigorsch SU; Devečka M; Dapper H; Weichert W; Friess H; Braren R; Combs SE; Habermehl D
Radiat Oncol; 2018 Aug; 13(1):139. PubMed ID: 30068371
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
[TBL] [Abstract][Full Text] [Related]
8. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Mehanna H; Robinson M; Hartley A; Kong A; Foran B; Fulton-Lieuw T; Dalby M; Mistry P; Sen M; O'Toole L; Al Booz H; Dyker K; Moleron R; Whitaker S; Brennan S; Cook A; Griffin M; Aynsley E; Rolles M; De Winton E; Chan A; Srinivasan D; Nixon I; Grumett J; Leemans CR; Buter J; Henderson J; Harrington K; McConkey C; Gray A; Dunn J;
Lancet; 2019 Jan; 393(10166):51-60. PubMed ID: 30449623
[TBL] [Abstract][Full Text] [Related]
10. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
[TBL] [Abstract][Full Text] [Related]
11. Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy.
Sher DJ; Thotakura V; Balboni TA; Norris CM; Haddad RI; Posner MR; Lorch J; Goguen LA; Annino DJ; Tishler RB
Ann Oncol; 2012 Sep; 23(9):2391-2398. PubMed ID: 22425872
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous integrated boost using intensity-modulated radiotherapy compared with conventional radiotherapy in patients treated with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma.
Clavel S; Nguyen DH; Fortin B; Després P; Khaouam N; Donath D; Soulières D; Guertin L; Nguyen-Tan PF
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):582-9. PubMed ID: 21277695
[TBL] [Abstract][Full Text] [Related]
13. Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan.
Saito Y; Hayashi R; Iida Y; Mizumachi T; Fujii T; Matsumoto F; Beppu T; Yoshida M; Shinomiya H; Kamiyama R; Kitano M; Yokoshima K; Fujimoto Y; Hama T; Yamashita T; Okami K; Miura K; Fujisawa T; Sano D; Kato H; Minami S; Sugasawa M; Masuda M; Ota I; Iwae S; Kawata R; Monden N; Imai T; Asakage T; Okada M; Yoshikawa T; Tanioka K; Kitayama M; Doi M; Fujii S; Fujii M; Oridate N; Nakamizo M; Yoshimoto S; Homma A; Nibu KI; Yane K
Cancer; 2020 Sep; 126(18):4177-4187. PubMed ID: 32648953
[TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease.
Bhattasali O; Han J; Thompson LDR; Buchschacher GL; Abdalla IA; Iganej S
Oral Oncol; 2018 Mar; 78():151-155. PubMed ID: 29496043
[TBL] [Abstract][Full Text] [Related]
15. Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy.
Hu Q; Li F; Yang K
PeerJ; 2024; 12():e17391. PubMed ID: 38784388
[TBL] [Abstract][Full Text] [Related]
16. Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck.
Kharofa J; Choong N; Wang D; Firat S; Schultz C; Sadasiwan C; Wong S
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):690-5. PubMed ID: 22112556
[TBL] [Abstract][Full Text] [Related]
17. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer.
Koutcher L; Sherman E; Fury M; Wolden S; Zhang Z; Mo Q; Stewart L; Schupak K; Gelblum D; Wong R; Kraus D; Shah J; Zelefsky M; Pfister D; Lee N
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):915-22. PubMed ID: 20947269
[TBL] [Abstract][Full Text] [Related]
18. Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin.
Corry J; Bressel M; Fua T; Herschtal A; Solomon B; Porceddu SV; Wratten C; Rischin D
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):948-954. PubMed ID: 28483336
[TBL] [Abstract][Full Text] [Related]
19. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
Oliva M; Huang SH; Xu W; Su J; Hansen AR; Bratman SV; Ringash J; Jang R; Cho J; Bayley A; Hope AJ; Chen E; Giuliani M; Waldron J; Weinreb I; Perez-Ordonez B; Chepeha D; Kim J; O Sullivan B; Siu LL; Spreafico A
Eur J Cancer; 2019 Sep; 118():112-120. PubMed ID: 31330486
[TBL] [Abstract][Full Text] [Related]
20. Validation of the 8
van Gysen K; Stevens M; Guo L; Jayamanne D; Veivers D; Wignall A; Pang L; Guminski A; Lee A; Hruby G; Macleod P; Taylor A; Eade T
BMC Cancer; 2019 Jul; 19(1):674. PubMed ID: 31288767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
